Marc Bonnin
Lyon, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
A Chemically Defined TLR3 Agonist with Anticancer Activity.
Journal: Oncoimmunology
Published: June 30, 2023
TL-532, a novel specific Toll-like receptor 3 agonist rationally designed for targeting cancers: discovery process and biological characterization.
Journal: Microbial cell (Graz, Austria)
Published: November 30, 2022
Corrigendum to "Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis" [J Hepatol 71 (2019) 763-772].
Journal: Journal of hepatology
Published: November 30, 2019
Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis.
Journal: Journal of hepatology
Published: January 29, 2019
Characterization of Pattern Recognition Receptor Expression and Functionality in Liver Primary Cells and Derived Cell Lines.
Journal: Journal of innate immunity
Published: February 07, 2018
Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis.
Journal: Cell death & disease
Published: December 01, 2017
Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes.
Journal: Scientific reports
Published: October 25, 2017
Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells.
Journal: Antimicrobial agents and chemotherapy
Published: August 23, 2017
Expression and functionality of Toll- and RIG-like receptors in HepaRG cells.
Journal: Journal of hepatology
Published: June 05, 2014
Cleaved/associated TLR3 represents the primary form of the signaling receptor.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: December 21, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026